title: [Pharmacovigilance].
abstract: Main pharmacovigilance updates in 2011 are reviewed. Dronedarone: Serious cardio-vascular and hepatic adverse reactions for a questionable efficacy. Long-term proton pump inhibitors: A cause of hypomagnesemia. Bisphosphonates: A risk of atypical femoral fractures. Dasatinib: Cases of pulmonary arterial hypertension reported. Lenalidomide: A risk of second primary malignancies. Daptomycine: Cases of eosinophilic pneumonia reported. Tigecycline: Inferior to comparators. Drotrecogin alfa: Market withdrawal due to lack of efficacy. Nimesulide: More hepatotoxic than other NSAIDs. Topiramate: Evidence of teratogenicity (oral clefts). Valproate: Impaired cognitive development in addition to well-known teratogenicity. Antipsychotics in late pregnancy: A risk of neonatal complications.
authors.affiliation: Division de pharmacologie et toxicologie cliniques, Département de médecine CHUV, 1011 Lausanne. francoise.livio@chuv.ch
authors.forename: F
authors.initials: F
authors.lastname: Livio
authors.forename: D
authors.initials: D
authors.lastname: Renard
authors.forename: T
authors.initials: T
authors.lastname: Buclin
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006785:Hospitals, University; D006801:Humans; D060735:Pharmacovigilance; D013557:Switzerland